LAVAL, Quebec May 2 Valeant Pharmaceuticals
International Inc, weighed down by debt from years of
acquisitions, is on pace to meeting its target of repaying $5
billion in debt between August, 2016 and February, 2018, Chief
Executive Joe Papa told shareholders on Tuesday.
Repayment is expected to come from asset sale proceeds and
free cash flow, and the company has earlier announced sales that
will generate up-front proceeds of $2.35 billion.
(Reporting by Allison Lampert in Laval, Quebec; writing and
additional reporting by Rod Nickel in Winnipeg, Manitoba;
Editing by Chizu Nomiyama)